BC Extra | Nov 19, 2019
Clinical News

Big gain for Myovant as oral prostate cancer therapy heads for submission

Myovant shares more than doubled in value Tuesday after the company revealed Phase III data showing its oral GnRH receptor antagonist relugolix led to sustained testosterone suppression in 96.7% of prostate cancer patients in Phase...
BC Extra | Jul 12, 2018
Politics & Policy

ICER panel votes against elagolix for endometriosis

An ICER panel showed little confidence in the clinical effectiveness of elagolix (ABT-620) from AbbVie Inc. (NYSE:ABBV) to treat endometriosis, voting Thursday that evidence is not adequate to support a net health benefit over other...
BC Week In Review | Nov 10, 2017
Clinical News

Myovant and Takeda's relugolix meets in Phase III for uterine fibroid pain

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and partner Myovant Sciences GmbH (NYSE:MYOV) reported top-line data from the Phase III TAK-385-3008 trial in 65 women with pain associated with uterine fibroids showing that once-daily 40 mg oral...
BC Week In Review | Oct 6, 2017
Clinical News

Myovant's relugolix meets in Phase III for uterine fibroids

Myovant Sciences GmbH (NYSE:MYOV) and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said relugolix (TAK-385) met the primary endpoint of non-inferiority to leuprorelin acetate in reducing menstrual bleeding in the Japanese Phase III TAK-385/CCT-002 trial to...
BC Extra | Oct 3, 2017
Clinical News

Myovant's relugolix meets in Phase III for uterine fibroids

Myovant Sciences GmbH (NYSE:MYOV) and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said relugolix (TAK-385) met the primary endpoint of non-inferiority to leuprorelin acetate in reducing menstrual bleeding in the Japanese Phase III TAK-385/CCT-002 trial to...
BioCentury | Jan 14, 2017
Strategy

Solidifying Takeda’s position

Takeda Pharmaceutical Co. Ltd. ’s proposed acquisition of Ariad Pharmaceuticals Inc. should be the boost the pharma needs to hit $10 billion in cancer sales by 2025, as the biotech’s brigatinib is expected to lead...
BioCentury | May 30, 2016
Strategy

Taking Takeda global

Two years after joining Takeda Pharmaceutical Co. Ltd. , Christophe Weber has narrowed the company's therapeutic focus, expanded the executive team and reorganized its approach to market with the aim of transforming the company into a...
BioCentury | Mar 14, 2016
Politics, Policy & Law

Value demonstration

Acting Administrator Andy Slavitt is pitting CMS against oncologists, hospitals, the pharmaceutical industry and congressional Republicans with a proposal to conduct a massive, nationwide controlled experiment testing value-based payments for drugs provided through Medicare Part...
BC Week In Review | Feb 15, 2016
Clinical News

Firmagon degarelix: Phase IIIb started

Ferring began the single-blind, North American Phase IIIb PRONOUNCE trial to compare Firmagon to Lupron Depot leuprolide for 1 year in about 900 patients with prostate cancer and CV disease. Firmagon is marketed in about...
BC Week In Review | Sep 22, 2014
Clinical News

Leuplin leuprorelin acetate regulatory update

Takeda submitted an NDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for a 6-month formulation of Leuplin leuprorelin acetate to treat prostate cancer and premenopausal breast cancer. Leuplin is available in about 80...
Items per page:
1 - 10 of 48